Inactivated Pepsin Fraction (IPF) Recognizes Viral Antigens

Most people infected with hepatitis C virus (HCV) do not have any acute signs or symptoms of hepatitis. They usually remain unaware that they have been infected during the first 10‐20 years, unless they have a blood test. They will usually be found to have some elevations of liver enzymes in their blood, as a result of leakage of these enzymes from damaged or dying liver cells. Specific blood tests can determine the presence of antibodies to HCV, or measure the blood level of HCV RNA, also known as viral load, by polymerase chain reaction detectable within 45‐90 days.

The precise mechanisms by which HCV infection causes liver damage are not known; however, there is strong evidence that a person’s own immunologic response to HCV contributes significantly to this process. The final outcome of infections by viruses that cause chronic diseases is believed to depend mostly upon the rate of replication of the infecting virus and the capacity of the immune system to mount rapid, multispecific and efficient virusspecific responses to inhibit infection before the virus can devise strategies to evade immune surveillance.

HCV is a single‐stranded RNA virus which does not integrate into the host’s genetic material. HCV must constantly replicate to maintain its presence in the human body and is very efficient at replicating inside of human cells. The clinical significance of extra hepatic HCV is not fully understood, and it is difficult to definitively determine the presence of replication in the absence of an in vivo model.
In a recent publication, Laskus documented evidence of HCV replication in peripheral blood cells (monocytes/macrophages, and T and B cells) in HCV/HIV coinfected patients. He suggests that HCV may replicate in the same cells infected with HIV and that there may be direct interactions between the two viruses. When interferon alfa (IFN) therapy is given to people with HCV infection, there is two‐phase decay. There is an initial rapid decrease in HCV RNA, then a secondary, slower decay, or decrease.

The initial decay, about a 1.5 log decrease in HCV RNA seen during the first 48 hours, is thought to represent the death of HCV‐infected hepatocytes, or liver cells. Studies have shown that neutralizing antibodies are produced during HCV infection, but they do not appear to be protective against re‐infection in humans or in chimpanzees. The more critical determinate of the outcome of HCV infection seems to be the cell‐mediated immune response, or the T‐ Cell (CD4) response.

People who are able to spontaneously clear HCV from their body have evidence of strong T‐cell responses. Conversely, people who are chronically infected with HCV do not appear to either mount a strong T‐cell response early after HCV infection, or maintain an initial strong T‐cell response to HCV antigens. In Gerlach’s study, the 20 people (52.6%) out of 38 studied who cleared HCV infection all had a strong sustained antiviral T‐cell response to HCV, while the people who became chronically infected either showed no initial T‐cell
response (12, 31.6%) or did not maintain an initial strong antiviral T‐cell response (6, 15.8%). Over time, however, in most people chronically infected with HCV, T‐cell responses increase but are not able to clear HCV.

Possible Strategies for a Virus to Escape Immune Elimination
1. Decrease its visibility to the immune system.
2. Decrease the effectiveness of antiviral cytokines.
3. Increase the resistance of infected cells to CTL‐mediated killing.
4. Infect immunologically privileged sites.
5. Induce immunologically tolerance.
6. Immunologic evasion

While HCV is an RNA virus, it is not a retrovirus; therefore, HCV does not incorporate its genetic code into the host cell’s DNA. So if all infected liver cells, or hepatocytes, and any other cells in the body which are infected with HCV die—and there are no free HCV virions around to infect new cells‐then the person will no longer be infected with HCV (i.e., the infection will be eradicated). Some investigators
believe that most people who remain without detectable HCV RBA six months after therapy have achieved eradication (i.e., they are cured). Approximately 15% of people acutely infected with HCV are able to achieve life‐long eradication of HCV from their body by their immune response. Whether people are in fact cured will require longer follow‐up; however, there is an important implication to achieving eradication. People can be re‐infected with HCV after they have had the initial HCV infection eradicated; there is no life‐long HCV immunity.

The nature of the receptors enabling hepatitis C virus (HCV) entry into cells has been the subject of debate. On one hand, ligand panning with recombinant HCV envelope protein has indentified CD81, a member of the tetraspanin superfamily of proteins, as a direct ligand for the E2 glycoprotein. On the other, virus present in infected blood is found associated with low‐density lipoprotein (LDL) and the LDL receptor (LDL‐R) has been suggested as a receptor for the virus. Zhabilov discloses method for isolating and preparing an inactivated pepsin fraction (IPF) useful for detecting and treating HIV1 HCV and some autoimmune and viral diseases. According to preliminary trials the complex antigen of IPF and viral antigens together through alfa 1 alfa 2 and beta serum fractions which form inside the body, blocks contact virus and hepatocytes and immune cells at the same time trigger an immune reaction.

The new antigen complex triggers an immune reaction model
with the participation of T lymphocytes with gamma‐delta chains of their surface. In this way, IPF appears like an immune creator and can be used for treatment of HCV infection. The results of this approach by using IPF SA immune creator that takes part in creating a complex antigen having the properties of a vaccine. The new antigen complex triggers an immune reaction model with the participation of T lymphocytes. The results of the pilot testing study conducted clearly show the action and effectiveness of IPF. Immunological results by Dr. Santos from Centro Medico Nova in Mexico are:

1. Increase in percentage and numbers of CD8 positive cells in the treated patients
2. Significant decline CD8+CD38+cells in treated patients
3. Significant increase in both the CD4+iNFg secreting cells as well as the CD8+iNFg secreting cells
in the treated patients
4. Increase all the cytokines such as IL2 IL6 IL12 relate with the TH1 immune response

All of the above immunological changes show the immunological effect of IPF. The shown
immunological results can open a window for the creation of vaccine treating against viral diseases such
as HCV.

Written by: Harry Zhabilov
President and Chief Science Officer

Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C.
Arthritis Rheum 42:2204-12, 1999.
Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C
virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Medicine
(Baltimore) 79:47-56, 2000.
Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunologic features of hepatic
injury and viral persistence. Hepatology 30:595-601, 1999.
Chang K. The mechanisms of chronicity in hepatitis C virus infection. Gastroenterology 115:
1015-17, 1998.
Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with
hepatitis C virus. Science 258:135-40, 1992.
Ferrari C, Urbani S, Penna A, et al. Immunopathogenesis of hepatitis C virus infection. J Hepatol
31:31S-38S, 1999.
Gerlach JT, Diepolder HM, Jung MC, et al. Recurrence of hepatitis C virus after loss of virusspecific
CD4+ T cell response in acute hepatitis C. Gastroenterology 117:933-41, 1999.
Gretch DR, Chang M, Williams O, et al. Active replication of HCV in human liver tissue shows
a significant correlation with severity of hepatitis C In vivo [abstract]. Hepatology 30:353A,
Laskus T, Radkowski M, Piasek A, et al. Hepatitis C Virus in lymphoid cells of patients
coinfected with human immunodeficiency virus type 1: evidence of active replication in
monocytes/macrophages and lymphocytes. J Infect Dis 181:442-8, 2000.
Laskus T, Radkowski M, Wang LF, et al. Search for hepatitis C extrahepatic replication sites in
patients with acquired immunodeficiency syndrome: specific detection of negative strand viral
RNA in various tissues. Hepatology 28:1398-1401, 1998.
Manns MP, Rambusch EG. Autoimmunity and extrahepatic manifestations in hepatitis C virus
infection. J Hepatol 31:39S-42S, 1999.
Mika BP, McCarthy ME, Layden TJ, et al. HIV/HCV co-infected patients experience HCV viral
rebound after the second day of IFN treatment [abstract]. Hepatology 30:195A, 1999.
Min A, Jones J, Esposito S, et al. Early hepatitis C viral RNA decline during therapy with
interferon alfa-2b and ribavirin in patients with chronic hepatitis C without sustained response to
prior interferon [abstract]. Hepatology 28:A29, 1998.
Munoz S, Suvannasankha A, DiGregorio K, et al. Retreatment with ribavirin and interferon
alpha 2b of relapsers and nonresponders to monotherapy [abstract]. Hepatology 28:A28, 1998.
Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral
efficacy of interferon-alpha therapy. Science 282:103-7, 1998.
Perelson AS. HCV dynamics: a guide to patient management [slide lecture & syllabus]. AASLD,
Postgraduate Course, Dallas, 5 November 1999.
Perelson AS. Viral kinetics and mathematical models. Am J Med 107:49S-52S, 1999.
Ramratnam B, Bonhoeffer S, Binley J, et al. Rapid production and clearance of HIV-1 and
hepatitis C virus assessed by large volume plasma apheresis. Lancet 354:1782-85, 1999.
Seeff LB. Hepatitis C. Semin Liver Dis 15:1, 1995.
Thomas DL, Astemborski J, Vlahov D, et al. Determinants of the quantity of hepatitis C virus
RNA. J of Infect Dis 181:844-51, 2000.
Vucelic B, Ostojic A, Hrstje B, et al. Viral kinetic study of induction dosing with interferon
alpha and ribavirin in the treatment of chronic hepatitis C [abstract]. Hepatology 28:A32, 1998.
Walsh KM, Good T, Cameron S, et al. Viral kinetics can predict early response to alphainterferon
in chronic hepatitis C. Liver 18:191-5, 1998.
Yasui K, Okanoue T, Murakami Y, et al. Dynamics of hepatitis C viremia following interferonalpha
administration. J Infect Dis 177:1475-9, 1998.
Zeuzem S. Clinical implications of hepatitis C viral kinetics. J Hepatol 31:61S-4S, 1999.
V HIV HPV and genital herpes etc…..